drugset / Trial / NCT06328764
CS-101 in Patients With β-thalassemia
Phase 0
Enrolling by invitation
10 enrolled
CorrectSequence Therapeutics Co., Ltd
First Affiliated Hospital of Guangxi Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.
Timeline
- Start
- 2024-03-19
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-101 | Cell therapy | — | — |